- Trial phase
- Phase 3
- Time to market
- At least 2-4 years. The Phase 3 DLLEVATE trial is just being initiated, and a registrational path for NEC is also in planning. If Phase 3 data is positive, a BLA submission would follow, putting potential approval in the 2028-2030 timeframe.
- Why 4/10
- No specific dated binary catalyst (PDUFA, pivotal readout) is scheduled in the next ~12 months. The Phase 3 DLLEVATE trial is being initiated but no readout date has been disclosed. The drug is a major pipeline value driver but Zai Lab has multiple approved products and another late-stage asset (povetacicept PDUFA Nov 30, 2026), so zoci is not a single-asset binary.
Watch for the initiation and enrollment updates of the Phase 3 DLLEVATE trial and any NEC registrational data timeline. The PIPE's strong institutional participation (TCGX-led, with RA Capital, Wellington, Frazier) signals conviction, but the ~9% dilution is a near-term overhang. The stock's next major binary will be the DLLEVATE topline readout, no date set yet, but the $250M raise suggests a global pivotal program is imminent.
Price Chart
Executive Summary
zocilurtatug pelitecan (zoci) is Zai Lab's wholly-owned DLL3-targeting antibody-drug conjugate (ADC) for small cell lung cancer (SCLC) and neuroendocrine cancers. At ESMO 2026, it posted a striking 81.8% confirmed objective response rate (ORR) in first-line extensive-stage SCLC combined with atezolizumab, with only 9.1% Grade 3 treatment-related adverse events, a compelling efficacy/safety profile. On October 23, 2026, Zai Lab raised $250M via a PIPE from top healthcare investors specifically to fund zoci's global Phase 3 DLLEVATE trial and NEC registrational program. The stock trades at $24.03 with a mean analyst target of $33.14 (~38% upside). Zai Lab is already commercially profitable with approved products, reducing binary risk. However, the DLL3 space is getting crowded (Legend Biotech CAR-T, Molecular Partners Radio-DARPin, Roche/Zymeworks T-cell engager), and no specific Phase 3 readout date has been disclosed yet.
How It Works
An antibody-drug conjugate (ADC), a targeted cancer therapy that works like a guided missile. The antibody component recognizes and binds to DLL3, a protein found on the surface of small cell lung cancer and neuroendocrine cancer cells but rarely on healthy cells. Once bound, the drug is absorbed into the cancer cell, where it releases a chemotherapy payload to kill the cell from within. This approach aims to deliver potent chemotherapy directly to tumors while sparing most healthy tissue.
Trial Status
Presented Phase 1/2 data at ESMO 2026 showing 81.8% confirmed ORR in first-line extensive-stage SCLC (1L ES-SCLC) combined with atezolizumab, with a favorable 9.1% Grade 3 TRAE rate. A global Phase 3 trial (DLLEVATE) is being initiated, funded by the $250M PIPE closed October 2026. Registrational data in neuroendocrine carcinoma (NEC) is also planned.
The Two-Sided Case
Upcoming Catalysts
- Initiation and enrollment updates for Phase 3 DLLEVATE trial
- NEC registrational data readout (date TBD)
- Potential additional data presentations at medical conferences (ASCO, ESMO, etc.)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zai Lab Ltd 8-K ZLAB ·Originating report